Eton Pharmaceuticals acquires PKU GOLIKE® rights from Relief Therapeutics for phenylketonuria.

Eton Pharmaceuticals acquires U.S. rights to PKU GOLIKE® from Relief Therapeutics Holding SA for phenylketonuria (PKU), a rare inherited disorder. The acquisition is expected to be accretive to Eton's 2024 earnings and aims to increase awareness, education, and adoption of the medical formula. Eton plans to leverage its sales force and existing relationships in the metabolic community to enhance patient access to the product.

March 22, 2024
10 Articles